	US 11,834,713 B2
	Inhibitors of alpha-tubulin acetylation for the treatment of pain
Paul Heppenstall, Monterotondo (IT); and Shane Morley, Monterotondo (IT)
Assigned to EUROPEAN MOLECULAR BIOLOGY LABORATORY, Heidelberg (DE)
Filed by EUROPEAN MOLECULAR BIOLOGY LABORATORY, Heidelberg (DE)
Filed on Jul. 23, 2021, as Appl. No. 17/383,975.
Application 17/383,975 is a continuation of application No. 16/069,818, granted, now 11,104,949, previously published as PCT/EP2016/082765, filed on Dec. 28, 2016.
Claims priority of application No. 16151345 (EP), filed on Jan. 14, 2016.
Prior Publication US 2022/0002801 A1, Jan. 6, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C12Q 1/6886 (2018.01); C12Q 1/6876 (2018.01); A01K 67/027 (2006.01); G01N 33/573 (2006.01)

CPC C12Q 1/6876 (2013.01) [A01K 67/0276 (2013.01); G01N 33/573 (2013.01); A01K 2217/075 (2013.01); A01K 2217/206 (2013.01); A01K 2227/105 (2013.01); A01K 2267/0356 (2013.01); C12Q 2600/136 (2013.01); C12Q 2600/158 (2013.01); G01N 2333/91051 (2013.01)]

22 Claims

1. A method for reducing expression of ATAT1 in a subject experiencing mechanical pain mediated by sensory neurons, the method comprising:

administering to the subject an effective amount of a nucleic acid that is capable of reducing expression of ATAT1;

wherein the mechanical pain is selected from the group consisting of:

inflammatory pain, acute mechanical pain, chronic mechanical pain, mechanical hyperalgesia, mechanical allodynia, visceral pain, and labor pain.